37619-28-6

Basic information

• Product Name: methyl 2-[(4-methoxybenzoyl)amino]benzoate
• Synonyms: methyl 2-[(4-methoxybenzoyl)amino]benzoate
• CAS NO: 37619-28-6
• Molecular Formula: C₁₆H₁₅NO₄
• Molecular Weight: 285.2946
• Mol File: 37619-28-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 2-[(4-methoxybenzoyl)amino]benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-[(4-methoxybenzoyl)amino]benzoate(37619-28-6)
• EPA Substance Registry System: methyl 2-[(4-methoxybenzoyl)amino]benzoate(37619-28-6)

Safety Data

• Hazardous Substances Data: 37619-28-6(Hazardous Substances Data)

Upstream product

• 100-07-2 4-methoxy-benzoyl chloride 
• 134-20-3 2-carbomethoxyaniline 
• 100-09-4 4-methoxybenzoic acid 

Downstream Products

• 87165-92-2 4-methoxy-N-<2-(2-pyridinylacetyl)phenyl>benzamide 
• 34425-86-0 2-[(4-methoxybenzoyl)amino]benzoic acid 
• 153707-63-2 4-methoxy-N-<2-<1-hydroxy-2-(2-pyridinyl)ethyl>phenyl>benzamide 
• 153707-65-4 N-{2-[1-Hydroxy-2-(1-methyl-1,2,5,6-tetrahydro-pyridin-2-yl)-ethyl]-phenyl}-4-methoxy-benzamide 
• 58754-48-6 encainide 
• 18600-55-0 2-(4-methoxyphenyl)-4H-3,1-benzoxazin-4-one 

Relevant articles and documents

Asymmetric Synthesis of N-N Axially Chiral Compounds by Phase-Transfer-Catalyzed Alkylations

N-N axially chiral skeletons are significant structural motifs in natural products, pharmaceuticals, and functional materials. Herein we disclose a method for the asymmetric synthesis of N-N axially chiral compounds by phase-transfer catalysis. A wide range of N-N axially chiral quinazolinone derivatives were prepared in high yields with excellent stereoselectivities. Furthermore, the synthetic utility of the protocol was proved by large-scale reaction and transformation of the product. Density functional theory calculations provide insight into the mechanism.

Synthesis of some new glutamine linked 2,3-disubstituted quinazolinone derivatives as potent antimicrobial and antioxidant agents

A series of novel glutamine linked 2,3-disubstituted quinazolinone conjugates was synthesized from methyl anthranilate and different substituted acids and acid chlorides. The compounds 5a-l were prepared in good yields. All compounds were screened for their antibacterial activity against Gram-positive and Gram-negative bacteria and for antifungal activity against Candida albicans and Aspergillus flavus using paper disk diffusion technique. The minimum inhibitory concentrations of the compounds were also determined by agar streak dilution method. The compound 5b was found to exhibit the most potent in vitro anti-microbial activity. When tested for their antioxidant activity, compounds 5i and 5l showed potent radical scavenging activity, while compound 5g had moderate effect against 2,2-diphenyl-1-picrylhydrazyl, hydroxyl, nitric oxide, and superoxide radical scavenging assays. These results suggest that, the three quinazolinone analogs (5g, 5i, and 5l) could be considered as useful templates for future development to obtain more potent antioxidant agents.

NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT

The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused by an abnormal excess of melanin or a disease caused by melanocyte hyperplasia comprising the same as an active ingredient. The biarylamide derivative of the present invention inhibits melanin production and thus inhibits melanocyte hyperplasia. Therefore, a cosmetic composition comprising the biarylamide is excellent in a whitening effect, and a pharmaceutical composition comprising the biarylamide is effective in the prevention or treatment of pigmentation disorders of skin such as lentigo, melasma, freckle, etc. and malignant melanoma.

The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents

Forty-seven 2-benzoylaminobenzoic esters were synthesized and evaluated in anti-platelet aggregation, inhibition of superoxide anion generation, and inhibition of neutrophil elastase release assays. Most 2-benzoylamino-4-chlorobenzoic acid derivatives showed selective inhibitory effects on arachidonic acid (AA)-induced platelet aggregation. Among them, compounds 6b and 7b exhibited more potent inhibitory effects (ca. 200-fold) than aspirin. Additionally, compounds 1a and 5a showed strong inhibitory effects on neutrophil superoxide generation with IC50 values of 0.65 and 0.17 μM, respectively. However, compounds 6d and 6e exhibited dual inhibitory effects on platelet aggregation and neutrophil elastase (NE) release; therefore, these two compounds may be new leads for development as anti-inflammatory and anti-platelet aggregatory agents.

N2-aroylanthranilamide inhibitors of human factor Xa

Reversal of the A-ring amide link in 1,2-dibenzamidobenzene 1 (fXa K(ass) = 0.81 x 106 L/mol) led to a series of human factor Xa (hfXa) inhibitors based on N2-aroylanthranilamide 4. Expansion of the SAR around 4 showed that only smal

Process for production of encainide

An improved process for the preparation of 4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]benzanilide has been developed. The process comprises essentially three steps starting with methyl anthranilate and 2-picoline and features a novel low-pressure hydrogenation sequence.